The use of cangrelor in everyday clinical practice is increasing, especially in high-risk P2Y12 naïve patients presenting with ACS complicated by cardiogenic shock, high thrombotic burden, or cardiac arrest (Figure 1). The gene discussed is P2RY12; the disease is cardiac arrest.